vTv Therapeutics Inc.
NASDAQ:VTVT
Overview | Financials
| Company Name | vTv Therapeutics Inc. |
| Symbol | VTVT |
| Currency | USD |
| Price | 20.38 |
| Market Cap | 53,338,740 |
| Dividend Yield | 0% |
| 52-week-range | 12.62 - 26.99 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Paul J. Sekhri M.Sc., MSc |
| Website | https://www.vtvtherapeutics.com |
An error occurred while fetching data.
About vTv Therapeutics Inc.
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD




